AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are sinking 8% after the firm announced what Canaccord analyst Neil Maruoka deems “another disappointment for Macrilen,” …
On November 9th, AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) posted third-quarter financial earnings and held a conference call.
AEterna Zentaris (NASDAQ:AEZS) delivered a financial third-quarter report on Tuesday, November 8th that “modestly” underperformed Canaccord analyst Neil Maruoka‘s expectations “on a lighter …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are jumping nearly 5% after the biotech firm posted third-quarter results yesterday that with a pivotal clinical …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) reported financial and operating results for the third quarter ended September 30, 2016.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that it intends to raise $7,560,000 in gross proceeds in a registered direct offering to a single healthcare …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced it has successfully completed patient recruitment for the confirmatory Phase 3 clinical trial of Macrilen™ (macimorelin) as a …
By Dana Lyons A key gauge of biotechnology stocks is testing major trendline support presently – can it hold yet again? When this …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) and Specialised Therapeutics Asia (STA) announced the signing of an exclusive license agreement for the Company’s lead investigational anti-cancer …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that the remaining 8,064 Series B Common Share Purchase Warrants (the “Series B Warrants”) issued in connection with …
